1-9
Mini Review
Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis?
Noor Al-Dasooqi, Rachel J. Gibson, Joanne M. Bowen and Dorothy M. Keefe
11-25
Mini Review
Treatment of metastatic renal cell carcinoma
David J. Reeves and Chin Y. Liu
27-33
Original Article
A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma
Sun Jin Sym, Dae Ho Lee, Hye Jin Kang, Seung Hyun Nam and Ho Young Kim, et al.
35-43
Original Article
Open AccessNuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor
S. Harmsen, I. Meijerman, J. H. Beijnen and J. H. M. Schellens
45-51
Original Article
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies
Steven Attia, Sherry Morgan-Meadows, Kyle D. Holen, Howard H. Bailey and Jens C. Eickhoff, et al.
53-65
Original Article
Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models
Ute Hoch, Jennifer Lynch, Yuji Sato, Shigeki Kashimoto and Fumie Kajikawa, et al.
67-72
Original Article
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients
Emilio Bajetta, Maria Di Bartolomeo, Roberto Buzzoni, Erminia Ferrario and Katia F. Dotti, et al.
73-78
Original Article
A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer
Kiyoshi Mori, Hiroyuki Kobayashi, Yukari Kamiyama, Yasuhiko Kano and Tetsuro Kodama
79-86
Original Article
Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors
Jill Kolesar, Wei Huang, Jens Eickhoff, Kristine Hahn and Dona Alberti, et al.
87-94
Original Article
Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form
Beom Soo Shin, Hyoung Jun Kim, Seok Hyun Hong, Jong Bong Lee and Sang Wook Hwang, et al.
95-96
Erratum
Enhanced absorption and tissue distribution of paclitaxel following oral administration of DHP 107, a novel mucoadhesive lipid dosage form
Beom Soo Shin, Hyoung Jun Kim, Seok Hyun Hong, Jong Bong Lee and Sang Wook Hwang, et al.
97-108
Original Article
Population pharmacokinetics meta-analysis of plitidepsin (Aplidin®) in cancer subjects
Ricardo Nalda-Molina, Belén Valenzuela, Amelia Ramon-Lopez, Bernardo Miguel-Lillo and Arturo Soto-Matos, et al.
109-114
Original Article
Influence of the etiology of liver cirrhosis on the response to combined intra-arterial chemotherapy in patients with advanced hepatocellular carcinoma
Masahiro Kanayama, Hidenari Nagai and Yasukiyo Sumino
115-122
Original Article
Open AccessCarboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Corine Ekhart, Sjoerd Rodenhuis, Jan H. M. Schellens, Jos H. Beijnen and Alwin D. R. Huitema
123-132
Original Article
Irinotecan-induced mucositis is associated with changes in intestinal mucins
Andrea M. Stringer, Rachel J. Gibson, Richard M. Logan, Joanne M. Bowen and Ann S. J. Yeoh, et al.
133-142
Original Article
Role of copper transporters in resistance to platinating agents
Cara A. Rabik, Edward B. Maryon, Kristen Kasza, John T. Shafer and Catherine M. Bartnik, et al.
143-152
Original Article
Anticancer activities of sesquiterpene lactones from Cyathocline purpurea in vitro
Guoyi Ma, Li Chong, Zuqiang Li, Andrew H. T. Cheung and Martin H. N. Tattersall
153-159
Original Article
Pharmacokinetics and tissue distribution of Kendine 91, a novel histone deacetylase inhibitor, in mice
Dorleta Otaegui, Alicia Rodríguez-Gascón, Aizpea Zubia, Fernando P. Cossío and José Luis Pedraz
161-167
Original Article
Phase I study of the combination of docetaxel, temozolomide and cisplatin in patients with metastatic melanoma
Kevin B. Kim, Wen-Jen Hwu, Nicholas E. Papadopoulos, Agop Y. Bedikian and Luis H. Camacho, et al.
169-170
Clinical Trial Report
Intrathoracic injection of paclitaxel for a patient with stage IV serous ovarian cancer: a case report
Takashi Mitamura, Masayoshi Hosaka, Mahito Takeda, Hidemichi Watari and Noriaki Sakuragi
171-175
Clinical Trial Report
Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study
Patrick D. Beauchesne, L. Taillandier, V. Bernier and C. Carnin
177-181
Short Communication
Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report
Anubha Bharthuar, Lori Egloff, Joanne Becker, Marina George and James W. Lohr, et al.
183-188
Short Communication
MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents
Erica L. Woodahl, Matthew H. Crouthamel, Tot Bui, Danny D. Shen and Rodney J. Y. Ho
189-193
Short Communication
To widen the setting of cancer patients who could benefit from metronomic capecitabine
Margherita Nannini, Elisabetta Nobili, Roberto Di Cicilia, Giovanni Brandi and Alessandra Maleddu, et al.
195-197
Short Communication
Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?
Massimo Breccia, Anna Maria Frustaci, Laura Cannella, Simona Soverini and Caterina Stefanizzi, et al.
199-200
Letter to the Editor
Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer
Sara N. Richter, Matteo Nadai, Manlio Palumbo and Giorgio Palù
201-211
Commentary
Do anthocyanins and anthocyanidins, cancer chemopreventive pigments in the diet, merit development as potential drugs?
Sarah Thomasset, Nicole Teller, Hong Cai, Doris Marko and David P. Berry, et al.